2-苯胺嘧啶-5-羧酸 | 450368-25-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-苯胺嘧啶-5-羧酸
• 中文别名: 2-苯胺并嘧啶-5-羧酸
• 英文名称: 2-(phenylamino)pyrimidine-5-carboxylic acid
• 英文别名: 2-Anilinopyrimidine-5-carboxylic acid
• CAS: 450368-25-9
• 化学式: C₁₁H₉N₃O₂
• 分子量: 215.211
• InChiKey: ZPIYMRAJXNMUPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36
• WGK Germany：
  3
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-苯胺嘧啶-5-羧酸 在 三乙基硅烷 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 15.0h， 生成 N-(5-(2-mercaptoacetamido)pentyl)-2-(phenylamino)pyrimidine-5-carboxamide
  参考文献：
  名称：

  硫醇基组蛋白脱乙酰酶6抑制剂的合成及构效关系

  摘要：

  选择性组蛋白去乙酰化酶 6 (HDAC6) 抑制剂安全且耐受性良好，脱靶效应较小。然而，大多数可用的 HDAC6 抑制剂含有异羟肟酸盐作为锌结合基团 (ZBG)，其不利的药代动力学特性以及潜在的遗传毒性限制了其在多种疾病中的广泛应用。因此，我们设计并合成了一系列以硫醇为ZBG的选择性HDAC6抑制剂，并基于分子对接讨论了它们的构效关系。特别是化合物21，通过基于 Ricolinostat（一种处于 II 期的特异性 HDAC6 抑制剂）不断逐步简化和进化获得的，出乎意料地显示出高选择性（29 倍）和中等效力（73 nM）。在基于硫醇的 HDAC6 抑制剂中使用嘧啶作为接头会产生一种全新的结构，该结构可能显示出不同的药代动力学特性和遗传毒性。

  DOI：

  10.1111/cbdd.14055
• 作为产物：
  描述：

  (5-溴嘧啶-2-基)苯胺 在 水 、 palladium diacetate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 2-苯胺嘧啶-5-羧酸
  参考文献：
  名称：

  Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib

  摘要：

  Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-Raf(V600E) inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure-activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-Raf(V600E) mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf(V600E) dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-Raf(V600E) inhibitor therapy.

  DOI：

  10.1021/jm500007h

文献信息

• [EN] SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDE SUBSTITUÉS EN TANT QU'INHIBITEURS DE DGAT-1
  申请人：MERCK SHARP & DOHME

  公开号：WO2012024179A1

  公开（公告）日：2012-02-23

  Described herein are compounds of formula I. The compounds of formula I act as DGAT-1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述的是I式化合物。公式I的化合物作为DGAT-1抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• Development of second generation EP2 antagonists with high selectivity
  作者：Thota Ganesh、Jianxiong Jiang、Ray Dingledine

  DOI：10.1016/j.ejmech.2014.05.076

  日期：2014.7

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.
• JPH03127790A
  申请人：——

  公开号：JPH03127790A

  公开（公告）日：1991-05-30
• US6759412B2
  申请人：——

  公开号：US6759412B2

  公开（公告）日：2004-07-06
• Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
  作者：Huimin Cheng、Yu Chang、Lianwen Zhang、Jinfeng Luo、Zhengchao Tu、Xiaoyun Lu、Qingwen Zhang、Jibu Lu、Xiaomei Ren、Ke Ding

  DOI：10.1021/jm500007h

  日期：2014.3.27

  Epidermal growth factor receptor (EGFR) amplification has been demonstrated to be critical for the inherent and/or acquired resistance against current B-Raf(V600E) inhibitor therapy for melanoma and colorectal cancer patients. We describe the discovery and structure-activity relationship study of a series of 1H-pyrazolo[3,4-b]pyridine-5-carboxamide analogues as novel dual inhibitors of EGFR and B-Raf(V600E) mutant. One of the most promising compounds, 6a, potently inhibited both of the kinases with IC50 values of 8.0 and 51 nM, respectively. The compound also strongly suppressed the proliferation of a panel of intrinsic and acquired resistant melanoma and/or colorectal cancer cells harboring overexpressed EGFR with submicromolar IC50 values. Further mechanism investigation revealed that 6a could sustainably inhibit the activation of the MAPK path way in the resistant SK-MEL-28 PR30 melanoma cancer cells and WiDr colorectal cancer cells with EGFR amplification. Our results support the hypothesis that the EGFR/B-Raf(V600E) dual inhibition might be a tractable strategy to overcome the intrinsic and acquired resistance of melanoma and/or colorectal cancers against the current B-Raf(V600E) inhibitor therapy.